Eric Hsu
Corporate Officer/Principal bei INMED PHARMACEUTICALS INC.
Vermögen: 19 $ am 31.03.2024
Profil
Eric C.
Hsu is currently the Vice President-Preclinical Research & Development at InMed Pharmaceuticals, Inc. Prior to this, he worked at enGene, Inc. for 16 years as the VP-Scientific Affairs, Research & Operations.
He completed his undergraduate degree at McGill University and received his doctorate from the University of Toronto in 1999.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 04.03.2024 | 51 ( 0,00% ) | 19 $ | 31.03.2024 |
Aktive Positionen von Eric Hsu
| Unternehmen | Position | Beginn |
|---|---|---|
| INMED PHARMACEUTICALS INC. | Corporate Officer/Principal | 13.03.2018 |
Ehemalige bekannte Positionen von Eric Hsu
| Unternehmen | Position | Ende |
|---|---|---|
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Chief Operating Officer | 01.01.2018 |
Ausbildung von Eric Hsu
| McGill University | Undergraduate Degree |
| University of Toronto | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| INMED PHARMACEUTICALS INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
